• This will change your mind about Biohacking and Psychedelics

  • Oct 25 2021
  • Durée: 1 h
  • Podcast
Page de couverture de This will change your mind about Biohacking and Psychedelics

This will change your mind about Biohacking and Psychedelics

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • In this week's Dealmaker Show Interview, Oren will talk to Doug Drysdale on Biohacking and Psychedelics. Doug Drysdale has chaired the board of directors of a NASDAQ-listed company and as a CEO for the past 13 years has built and turned around four pharmaceutical companies. During Doug’s 30 years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, and has raised $4 billion of both public and private capital. Previously, Doug served as Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008. Over this period, Doug raised approximately $3 billion of capital and managed lending syndicates including over 25 banks, to fund the company’s growth. Actavis was sold to Watson Pharmaceuticals in 2012 for EUR4.25 billion. Doug holds a bachelor’s degree in Microbial and Molecular Biology from the University of East Anglia in the U.K. and was recognized as Entrepreneur of the Year by Ernst and Young, in 2012.
    Voir plus Voir moins
Gestion et leadership Économie
Voir plus Voir moins

Ce que les auditeurs disent de This will change your mind about Biohacking and Psychedelics

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.